Company Description
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.
Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications.
It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform.
The company was founded in 1995 and is headquartered in Cleveland, Ohio. On January 5, 2024, Athersys, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Ohio.
| Country | United States |
| Founded | 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Gil Van Bokkelen |
Contact Details
Address: 3201 Carnegie Avenue Cleveland, Ohio 44115-2634 United States | |
| Phone | 216-431-9900 |
Stock Details
| Ticker Symbol | ATHXQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001368148 |
| Employer ID | 20-4864095 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Z. Kasey Rosado | Interim Chief Financial Officer |
| Senthil Ranganathan Ph.D. | Vice President of Technical Operations |
| David Russ M.B.A. | Vice President of Supply Chain, Finance and Administration |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Executive Vice President and Head of Global Regulatory Affairs |
| Dr. Robert Mays Ph.D. | Executive Vice President, Head of Regenerative Medicine and Neuroscience Programs |
| Rakesh Ramachandran MS | Head of Information Technology and Communications and Vice President |
| Dr. Sarah Busch Ph.D. | Vice President of Regenerative Medicine and Head of Business Development |
| Ellen Gurley | Manager of Corporate Communications and Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Jan 8, 2024 | 8-K | Current Report |
| Dec 27, 2023 | 25-NSE | Filing |
| Dec 22, 2023 | 8-K | Current Report |
| Dec 4, 2023 | 424B3 | Prospectus |
| Nov 29, 2023 | EFFECT | Notice of Effectiveness |
| Nov 22, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 16, 2023 | 10-Q | Quarterly Report |
| Nov 14, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |